KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Mankind launches ‘Act at 30’ campaign to push early heart health screening

Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone

Senores Pharma doubles profit as sales surge 62%

Global specialty pipeline accelerates growth

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Gilead posts solid Q1 2026 growth & raises full-year outlook on HIV momentum